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Mesenchymal stem/stromal cells (MSCs) exhibit multidifferentiation potential, paralleled with immunomodulatory and trophic
properties that make them viable alternative tools for the treatment of degenerative disorders, allograft rejection, autoimmune
diseases, and tissue regeneration. MSC functional attributes can be modulated by exposing them to inflammatory-stimulating
microenvironments (i.e., priming) before their therapeutic use. Granulocyte-colony stimulating factor (G-CSF) is a cytokine that
plays key roles in immune response and hematopoiesis modulation through direct effects on hematopoietic progenitors’
proliferation, survival, and mobilization. Despite the established roles of MSCs supporting hematopoiesis, the effects of G-CSF
on MSCs biology have not been thoroughly explored. This study reveals that G-CSF has also direct effects on adipose-derived
MSCs (ADSCs), modulating their functions. Herein, microarray-based transcriptomic analysis shows that G-CSF stimulation
in vitro results in modulation of various signaling pathways including ones related with the metabolism of hyaluronan (HA),
conferring a profile of cell mobilization to ADSCs, mediated in a cell-intrinsic fashion in part by reducing CD44 expression and
HA synthesis-related genes. Collectively, these data suggest a direct modulatory effect of G-CSF on ADSC function, potentially
altering their therapeutic capacity and thus the design of future clinical protocols.
1. Introduction
Mesenchymal stem/stromal cells (MSCs) have emerged in
recent years as potential therapeutic tools for various clinical
conditions [1, 2]. This is based on important features such as
multidifferentiation potential, a strong capacity to modulate
bothadaptive and innate immune responses, inducible trophic
effects (e.g., angiogenic, mitogenic, antiapoptotic, and antifi-
brotic), and low immunogenicity that permits allogeneic ther-
apeutic regimes [3, 4]. The adipose tissue constitutes a rich
reservoir of MSCs, easily accessible through minimally inva-
sive procedures. Adipose-derived MSCs (ADSCs) exhibit fre-
quencies significantly higher than other sources such as the
“standard” bone marrow (BM) [5, 6]. MSCs are starting to be
recognized by their ability to sense their surroundingmolecu-
lar environment [7, 8] and to subsequently react with a broad
range of responses involving the paracrine secretion of soluble
and microvesicle-packaged molecules including growth fac-
tors, cytokines, and miRNAs [9, 10]. Importantly, those
responses can be antagonizing, as proinflammatory and anti-
Hindawi
Stem Cells International
Volume 2020, Article ID 5045124, 9 pages
https://doi.org/10.1155/2020/5045124
inflammatory cascades result from types 1 and 2MSC pheno-
typic shifting, respectively, dictated by the specific stimulatory
molecular environment [7, 8].
Granulocyte-colony stimulating factor (G-CSF) is a cyto-
kine, whose expression is induced by inflammatory stimuli
including IL-1β, IL-17, TNF-α, and LPS [11]. Its effects
are oriented mainly towards increasing the production
and mobilization of bone marrow-derived granulocytes of
neutrophilic identity as the response [12, 13]. G-CSF exerts
its biological effect through binding to its cognate receptor
G-CSFR (CD114), which is expressed in several cell types
including hematopoietic stem cells (HSPCs), precursor
and mature neutrophils, myeloid cell lines, endothelial cells,
placenta-derived cells, neurons, ovules, and cardiomyocytes
[14]. As for MSCs, Murakami et al. recently demonstrated
that ADSCs express CD114 (20:0% ± 1:7), which becomes
upregulated to 39:4% ± 4:7 when cells were mobilized
in vivo with G-CSF [15]. The resulting CD114/G-CSF com-
plex signals through multiple intracellular molecular path-
ways including Jak-STAT, Ras/MAPK, PI3K, and PKB/AKT
cascades, modulating various biological processes including
differentiation, migration, and survival [15, 16].
Due to an efficient granulocyte-mobilizing effect, recom-
binant human G-CSF (rhG-CSF) is now widely used
clinically in various conditions such as neutropenia due to
chemotherapy and myeloablative therapy followed by HSC
transplantation and in HIV infection [17, 18]. More recently,
it has been tested as an alternative and/or support to MSCs in
studies with ischemic conditions including the myocardium
and brain [19, 20] and for degenerative conditions of the cen-
tral nervous system [21]. Different rhG-CSF formulations are
currently approved as a biosimilar of filgrastim (Neupogen)
for its clinical use. IOR®leukoCIM is one of them, which
has comparable safety and pharmacodynamic and pharma-
cokinetic profiles demonstrated in vivo [22].
Beyond the known effects of G-CSF in HSPCs and its
current clinical use, to the best of our knowledge, there is
no description regarding potential activities of G-CSF on
MSCs and specifically on ADSCs functions. In the present
study, we show that two different formulations of rhG-CSF
have in vitro modulatory effects to the transcriptome of
ADSCs, inducing the activation of signaling pathways related
to cell proliferation, mobilization, differentiation, and sec-
ondary immune responses.
2. Materials and Methods
2.1. Isolation and Culture of Human Adipose Tissue-Derived
MSCs (ADSCs). The institutional Ethics Committee of the
Hospital Militar Central of Bogotá approved this study
(2013-049), with all samples (3 independent, de-identified,
healthy donors, ages 35, 37, and 39) obtained under written
informed consent. Adipose tissues (~40 g) were taken from
minimal abdominal lipoaspirate surgery, from which ADSCs
were isolated and cultured according to the following pro-
tocol. Briefly, adipose tissue was washed with equal vol-
umes of Dulbecco’s phosphate-buffered saline (DPBS),
and the extracellular matrix (ECM) digested with type I
collagenase 0.075% (Invitrogen-Gibco) at 37°C for 30min.
Enzyme activity was then neutralized with low-glucose
Dulbecco’s modified Eagle’s medium (LG-DMEM; Sigma-
Aldrich) containing 10% fetal bovine serum (FBS;
Invitrogen-Gibco) and 100U/ml penicillin/streptomycin
(PS; Invitrogen-Gibco). Samples were then centrifuged
and the cell pellet was seeded in T25 culture flasks in
LG-DMEM containing 10% FBS and 100U/ml PS. The
cells were incubated in a humidified atmosphere at 37°C
with 5% CO2, with the medium changed every 3 to 4 days
until the adherent fibroblast-like cells reached 70% conflu-
ence. The cells were then passaged twice by trypsin
(0.05%) digestion, seeded at a density of 5,000 cells/cm2
and finally used as Passage 2. Cell numbers and viability
at the time of passage were determined by trypan blue and
7-aminoactinomycin D (7AAD) methods, respectively.
2.2. Characterization of MSCs by Immunophenotypic
Analysis. Antibodies against the human antigens CD34
(PE), CD45 (FITC), CD105 (PerCP), CD73 (PE), and CD90
(FITC) were obtained from Becton Dickinson. A total of
1 × 105 cells/ml cells were resuspended in 0.2ml DPBS
and incubated with fluorescein isothiocyanate- (FITC-),
phycoerythrin- (PE-), or peridinin chlorophyll- (PerCP-)
conjugated antibodies for 30min at room temperature. The
fluorescence intensity of the cells was evaluated by flow
cytometry (FACS Canto II; Becton Dickinson), and the data
were analyzed using the FACS Diva software (Becton
Dickinson).
2.3. Osteogenic Differentiation Potential of ADSCs. Cells were
plated at density of 5 × 104 cells/well in 6-well plates in
LG-DMEMcontaining 10%FBS, allowed to adhere overnight,
and replaced with LG-DMEMcontaining 10%FBS and 1%PS
and supplemented with 0.1mM dexamethasone (Stemcell
Technologies), 10mM b-glycerol phosphate (Stemcell
Technologies), and 100mM ascorbate-2-phosphate (Stemcell
Technologies). The medium was changed every 3 days. After
14–21 days, osteoblast differentiation was determined by
alkaline phosphatase and von Kossa stainings.
2.4. Treatment of ADSCs with rhG-CSF. The optimal dose of
both rhG-CSF formulations [Innovator—Neupogen (Roche)
and Biosimilar—IOR®leukoCIM (Delta labs)] on ADSCs was
evaluated using the 7AAD cell viability staining, analyzed by
flow cytometry. ADSCS (1 × 105) from the 3 independent
donors were cultured in LG-DMEM containing 20% FBS,
1% PS, and rhG-CSF (100 and 200ng/ml of either formula-
tion) for 48 hours, with samples taken at 0, 8, 24, and 48
hours for analysis. Based on the resulting data, subsequent
experiments were performed with 200 ng/ml and similar
evaluation time points. These experiments involved the flow
cytometry evaluation (as described above) of CD44 (FITC) to
evaluate a migratory phenotype, along with CD90 to attest
general MSC phenotypic stability with both rhG-CSF
formulations.
For the high-throughput/transcriptomic analysis, 1 × 106
ADSCs were cultured in LG-DMEM containing 20% FBS, 1%
PS, and 200ng/ml of either rhG-CSF formulation for 6 hours.
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Individual wells were then harvested simultaneously for
RNA extraction.
2.5. RNA Isolation and Microarray Analysis. Control and
stimulated ADSCs were collected by treatment with 0.05%
trypsin-EDTA, and total cellular RNA was extracted from
pelleted cells and purified using a Quick-RNA™ MiniPrep
(Zymo Research) according to the manufacturer’s protocol.
RNA quality was determined by the OD 260/280 ratio, along
with quantification with NanoDrop spectrophotometer
(Thermo Scientific).
For microarray gene expression analysis, 2μg of total
RNA from ADSCs treated with either rhG-CSF formulation
or labeled with Cy3, while untreated counterparts were
labeled with Cy5 (used as reference) for their further hybrid-
ization on Agilent SurePrint G3 Human GE v2 8x60KMicro-
array (Agilent Technologies, Palo Alto, CA, USA), using the
RNA derived from the corresponding cells without prior
rhG-CSF treatment (labeled with Cy5) as reference. RNA
was obtained and processed from the 3 independent donors
(biological triplicate), run in duplicate (technical replicas).
The hybridization steps were carried out according to the
Agilent protocol and images were scanned using a Genepix
4000B microarray scanner (Axon Instruments, Foster City,
CA, USA). Image analysis and initial quality control were
performed using Agilent Feature Extraction Software v10.2.
Raw datasets have been submitted to GEO (GSE139352).
We used the Limma Bioconductor package for background
adjustment, within and between arrays normalization [23].
To identify significantly up- or downregulated genes within
the hybridized samples, we employed the one-class rank
products’ test (q value < 0.05; fold change > 1:5) [24].
2.6. Bioinformatic Analysis. Statistical analyses were done
with the MultiExperiment Viewer software (MeV 4.9) [25].
The number and identity of genes commonly affected in both
models were determined with Venn mapping. Functional
enrichment analyses were performed with InnateDB (https://
www.innatedb.com/index.jsp), REVIGO (http://revigo.irb.hr/),
and Cytoscape software (https://cytoscape.org).
3. Results
3.1. Isolation and Characterization of ADSCs. Processed adi-
pose tissue yielded ADSCs in culture with fibroblast-like
appearance and exhibiting fibroblast colony-forming units
(CFU-F) typical of MSC. Flow cytometric analysis showed
that ADSCs derived from all donors were positive for the typ-
ical MSC markers such as CD73, CD90, and CD105, while
negative for the hematopoietic markers CD34 and CD45
(Figure 1(a)). Expanded ADSCs exhibited a conserved poten-
tial to differentiate into osteoblasts (Figure 1(b)), indicating
that all populations were comprised of multipotent MSC.
3.2. Effect of G-CSF on ADSC Viability and Phenotype. The
7AAD viability assay showed that both formulations of
rhG-CSF (at both dose regimes) had no toxic effects on
ADSCs up to 48 hours, evidencing cell survival between 97%
and 98% throughout the stimulatory period (Figure 1(c)).
Based on this information, we used 200 ng/ml for subsequent
experiments. Importantly, CD90 was not impacted by G-CSF
treatment, which maintained expression between 94% and
96% (Figure 1(d)), thus evidencing a phenotypic stabilization
of ADSCs during the stimulation.
3.3. Effect of G-CSF on Expression of CD44 by ADSCs. Unlike
CD90, flow cytometry analysis revealed that CD44 presence
on ADSC was significantly reduced by rhG-CSF stimulation
throughout the treatment period, and as early as 8 hours.
CD44 experienced a reduction from ~85% (baseline) to
~45% with rhG-CSF (p < 0:05), while control cells had a
minor, yet not significant reduction to ~75% (Figure 1(e)).
3.4. Effect of G-CSF on ADSC Gene Expression Profiles In
Vitro and Common Bioprocesses. The primary goal of this
study was to identify commonly modulated pathways among
biosimilar and innovator G-CSF in ADSC. Microarray-based
gene expression profiling was performed on cell samples
isolated from the same individuals (n = 3), after 6 hours of
treatment with biosimilar or innovator G-CSFs and their cor-
responding untreated counterpart samples used as controls.
First, we performed an evaluation of gene expression profiles
associated with biosimilar and innovator G-CSF treatments,
to identify the most representative differentially expressed
transcripts for each drug. Second, we compared the biosimi-
lar and innovator G-CSF gene expression signatures, to iden-
tify the commonly modulated transcripts by both drugs.
Third, functional enrichment analysis was performed to
detect the G-CSF-modulated pathways in ADSC.
This statistical analysis revealed 458 commonly differen-
tially expressed transcripts across biosimilar and innovator
G-CSF (fold change ≥ 1:5; q < 0:05). Among the 458 tran-
scripts, 152 were upmodulated and 306 were downmodulated
transcripts in G-CSF treatments (Figures 2(a) and 2(b)). The
most commonly overexpressed transcripts in G-CSF treat-
ments were CDKN1C, CYP1B1, SLC40A1, HTR2B, and
DEPTOR, and the most commonly downexpressed were
NEFM, PODXL, KRT34, IL33, and KRTAP2-3. Functional
enrichment analysis of commonly deregulated transcripts
revealed bioprocess associated with innate immune response,
differentiation, and PI3K and MAPK signaling pathways
(p value < 0.001) as well as cell migration and cell adhe-
sion (p value < 0.001) (Figure 2(c) and Supplementary
Tables 1 and 2).
The commonly modulated bioprocess associated with the
rhG-CSF treatment of ADSCs can be grouped into two
groups: (i) upstream events of G-CSF treatment including
crosstalk among MAPK signaling, JAK-STAT and Wnt sig-
naling, and Hippo pathway, which are related to proliferation
and cell differentiation and (ii) downstream effects including
regulation of the actin cytoskeleton and cell mobilization
(Figure 3).
We selected genes for transcription factors playing a key
role in ADSC cell cycle regulation: HDAC2 and CCND1
(p = 0:03) and JAK-STAT pathway CCND1 and STAT1
(p = 0:04). These transcription factors were found signifi-
cantly upregulated in rhG-CSF-treated cells. This finding




The results for this study, the first work describing the effect
of in vitro stimulation for 6 hours of G-CSF on the ADSC
transcriptome, demonstrate that both G-CSFs (the innova-
tive and biosimilar) modulate the same gene expression
signature in ADSC cells. An interesting fact is given that
the development and manufacturing of biosimilar drugs are
increasing and there is a great interest in the continuous
development of analytical methods that can be used to
efficiently and effectively characterize biosimilars. Tran-
scriptomic analysis involves the study of gene expression
through the levels of mRNA present in cells exposed to treat-
ment in relation to a control test, which provides insight into
which biological pathways are active or inactive within the
cell. Therefore, the analysis of gene expression could be a tool
to evaluate the bioequivalence of biosimilar drugs.
Bioinformatic and data mining analysis suggest that
G-SCF induces upmodulation and downmodulation of genes
involved in several signaling pathways. Functional analysis
suggests enrichments of signaling pathways related with
cellular metabolism, activation of TLRs (innate immunity),
induction of the PI3K-Akt signaling pathway and activation
of the NFkB and MAP pathway (innate immunity), and
downregulation of genes associated with processes of cell
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Figure 1: Characterization of ADSC and stimulation with rhG-CSF. (a) ADSC immunophenotypic assessment as positive for CD73, CD90,
and CD105 and negative for CD34 and CD45. (b) Osteogenic differentiation of ADSCs after 14–21 days of induction, assessed by alkaline
phosphatase (Alk. Phos.) and von Kossa stainings, showing adequate mineralization of the ECM. (c) Cell viability assessed through 7AAD
assay analyzed at 8, 24, and 48 h, showing no toxicity with either formulation at both doses. (d, e) ADSC stimulation with both
formulations at 200 ng/ml, showing CD90 expression unaltered during the same time period (d), while CD44 was significantly reduced as
early as 8 hours post stimulation. ∗p < 0:001 when compared to time 0 for each condition.
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These data are important because they open the possibility of
deepening the relationship of this drug and influenced ADSC
cells when a patient undergoes therapeutic protocols of stim-
ulation with G-CSF.
The discussion of our results will be centered on the
possibility that ADSCs following G-CSF stimulation may
migrate, as their hematopoietic stem cells (HSPCs) counter-
part. This is a result of the regulation and interactions
between the pleiotropic signaling pathways and specific
cellular regulators identified in the transcriptome.
CD44 is a molecule expressed by many immune
cells and progenitors (i.e., hematopoietic stem/progenitor
cells—HSPCs). It is involved in several biological processes



























































































































Figure 2: Hierarchical cluster and Gene Ontology analysis of differentially expressed genes in ADSCs treated with G-CSF. (a) Heat map of
differentially expressed genes involved in G-CSF responses in ADSCs. (b) Venn diagrams showing high consistency between the two technical
replicas (R1 and R2) run for each biological triplicate for both Innovator and Biosimilar formulations (top 2 rows), and between them in terms
of upregulated and downregulated genes (lower row). (c) Functional annotation showed that genes could be grouped into a limited number of
biological categories. Most of the genes upregulated in ADSCs were enriched in innate immune response, differentiation, and MAPK cascade
(p value < 0.001), while most of the genes downregulated are involved in cell migration and cell adhesion (p value < 0.001).
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signaling molecules [26]. CD44 has a documented activity
inducing the mobilization and migration of immune cells
and progenitors from and to the bone marrow [27] and to
inflammatory sites and lymph nodes [28, 29], maintaining
them circulating during inflammation [30]. While CD44
expression in ADSCs has been documented [31], bone
marrow-derived MSC has been only shown to be induced
by inflammation and G-CSF [32].
We are showing by both transcriptomic and flow cyto-
metric analysis post stimulations with G-SCF a significant
reduction in CD44, a biologically interesting result given its
interaction with multiple ligands including hyaluronate
(HA), a highly expressed molecule in mesenchymal cells of
different origins [33]. CD44 activity has been well established
in HSPC regulation [34]. CD44/HA binding promotes cell
adhesion via cytokines/chemokines, quiescence, and resis-
tance to hypoxia in HSPCs [35]. Studies with mice have
shown that in HSPCs, the use of anti-CD44 antibodies is
associated with alteration in their “homing” to BM and
spleen [36]. In contrast, studies in CD44 KOmice (knockout)
showed no defects in this process [37]; however, a reduction
was found in the output of BM myeloid progenitor cells to
Figure 3: Molecular interaction networks and integration with gene expression profiles in ADSCs exposed to G-CSF in vitro (Cytoscape).
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the circulation [27]. In humans, it has been reported that
administration of G-CSF appears to result in faster mobiliza-
tion of CD34+ HSPCs [38, 39]. Furthermore, this mobiliza-
tion is associated with a downregulation in both CD44 and
CD31 from days 3 to 5 of continuous intravenous adminis-
tration, measured in peripheral blood CD34+ [40].
Based on the established mechanism involving the sup-
port of CD44 reduction in the mobilization of HSPCs, we
hypothesized that it could confer a similar migratory role to
ADSCs after stimulation with G-CSF. In fact, the transcrip-
tomic data supports that hypothesis. Our results showed a
concomitant reduced expression ofHAS1 andHAS2, respon-
sible genes for synthesizing hyaluronan (HA) at the inner
face of the plasma membrane [41]. Therefore, a probable
synergistic effect by the reduced CD44, HAS1 and HAS2
could lead to a reduction in the production and/or activity
of HA, negatively impacting its activity as an ECM ligand
anchoring ADSCs.
5. Conclusions
In conclusion, the G-CSF impacts the transcriptome of the
ADSCs modulating various pathways including ones related
with the metabolism of hyaluronan, conferring a profile of
cell mobilization (Figure 4). Collectively, to the best of our
knowledge, this is the first time that ADSC migratory capac-
ity is linked with G-CSF stimulation and specifically through
a reduction in CD44. This could potentially alter ADSC ther-
apeutic capacity and thus the design of future clinical proto-
cols, for instance, by stimulating/licensing them with G-CSF
prior to administration.
Data Availability
The raw datasets used to support the findings of this study
have been deposited in the Gene Expression Omnibus
(GEO) repository with the identifier GSE139352.
Additional Points
Highlights. Innovator and biosimilar G-CSF induce compa-
rable transcriptomic responses in ADSCs. G-CSF favors a cell
migration response mainly by altering hyaluronan (HA)
metabolism pathways. G-CSF downregulates CD44 and
HAS1/HAS2 genes. G-CSF decreases CD44 expression in
ADSCs in culture over time.
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Two tables are presented with significantly enriched molec-
ular pathways and upregulated (Supplementary Table 1)
and downregulated (Supplementary Table 2) genes in ADSCs
in vitro after stimulation with G-CSF. (Supplementary
Materials)
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